未经批准:糖尿病肾病(DKD),广义上定义为糖尿病患者的持续性蛋白尿,估计肾小球滤过率较低,是终末期肾病的主要病因.过量产生活性氧是DKD发病机理的重要机制,许多抗氧化剂已作为治疗剂进行了研究。其中,中药抗氧化应激疗法已被广泛用于对抗DKD,这可能为DKD的治疗发展提供新的见解。西药(WM)的功效与中药(CMF)的功效之间存在一些差异。
未经授权:我们搜索了PubMed,科克伦图书馆,WebofScience数据库,Embase,和Scopus从开始到2021年12月使用相关关键词,并对随机对照试验(RCT)进行了全面搜索.通过具有随机效应的逆方差方法计算合并加权平均差(MD)和95%CI。所有相关统计分析均使用Stata15.1版软件(StataCorporation)和Rvman5.3版(NordicCochraneCenter)进行。
UNASSIGNED:共8篇,其中9组包括模型组106篇,CMF组中的105,和99在WM组中。来自8项研究(9组)的汇总数据显示,与模型组[标准化MD(SMD)=1.57;95CI:1.16-1.98;P<0.05]和WM组(SMD=0.56;95CI:0.19-0.92;P<0.05)相比,超氧化物歧化酶有统计学改善。对于谷胱甘肽过氧化物酶(GSH-Px),CMF组与CMF组相比有显著改善模型组和WM组。对于丙二醛(MDA),在CMF组中显著降低(CMF与模型组:SMD=-1.52;95CI:-1.88-1.17;P<0.05;CMFvs.WM组:SMD=-0.64;95CI:-0.95-0.33;P<0.05)。
UNASSIGNED:本系统综述和荟萃分析表明,CMF治疗对缓解STZ诱导的DKD大鼠的氧化应激有显著疗效,且CMF明显优于WM对照组。对于临床应用,研究结果在一定程度上对CMF的疗效进行评价,为DKD提供了信心和一定的理论参考。
未经批准:[PROSPERO],标识符[CRD42022313737]。
UNASSIGNED: Diabetic kidney disease (DKD), defined broadly as persistent proteinuria with low estimated glomerular filtration rate in patients with diabetes, is a main cause of end-stage renal disease. Excessive production of reactive oxygen species is an important mechanism underlying the pathogenesis of DKD and many antioxidants have been investigated as therapeutic agents. Among them, Chinese medicine antioxidative stress therapies have been widely used to combat DKD, which may offer new insights into therapeutic development of DKD. There are several discrepancies among the efficacy of Western medicine (WM) and Chinese medicinal formula (CMF) action.
UNASSIGNED: We searched PubMed, Cochrane Library, the Web of Science databases, Embase, and Scopus from inception to December 2021 using relevant keywords and a comprehensive search for randomized controlled trials (RCTs) was performed. Calculating the pooled weighted mean difference (MD) and 95% CI by the method of inverse-variance with a random-effect. All the related statistical analyses were performed using Stata version 15.1 software (Stata Corporation) and Rvman version 5.3 (Nordic Cochrane Center).
UNASSIGNED: A total of 8 articles with the 9 groups including 106 in the model group, 105 in the CMF group, and 99 in the WM group. Pooled data from 8 studies (9 groups) showed a statistical improvement in superoxide dismutase compared with the model group [standardized MD (SMD) = 1.57; 95 CI: 1.16-1.98; P < 0.05] and the WM group (SMD = 0.56; 95 CI: 0.19-0.92; P < 0.05). For glutathione peroxidase (GSH-Px), it was significantly improved in the CMF group vs. the model group and the WM group. For malondialdehyde (MDA), it was significantly reduced in the CMF group (CMF vs. model group: SMD = -1.52; 95 CI: -1.88 -1.17; P < 0.05; CMF vs. WM group: SMD = -0.64; 95 CI: -0.95 -0.33; P < 0.05).
UNASSIGNED: This systematic review and meta-analysis have demonstrated that the therapy of CMF had a notable curative effect on relieving oxidative stress in STZ-induced DKD rats and CMF was significantly more effective than the WM control group. For the clinical application, the results providing confidence and some theoretical reference for DKD via evaluating the efficacy of CMF to a certain extent.
UNASSIGNED: [PROSPERO], identifier [CRD42022313737].